2. Centro Cardiologico Monzino, IRCCS, University School of Milan, Milan, Italy
3. 3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland
4. Department of Cardiovascular Medicine, Vilnius University, Vilnius, Lithuania
5. Department of Cardiovascular Medicine, Vilnius University, Vilnius, Lithuania
6. National Research Cardiac Surgery Center, Astana, Kazakhstan
7. American Heart Institute, Nicosia, Cyprus
8. Centre Hospitalier Universitaire “Charles Nicolle” de Rouen, France
9. Centre Hospitalier Universitaire, Hôpital Arnaud de Villeneuve, Montpellier, France
10. Clinica San Gaudenzio, Novara, Italy
11. Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
12. Centro Cardiologico Monzino, IRCCS, University School of Milan, Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, Milan, Italy
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
To read the full content of this article, please log in to download the PDF.
Methods and results: Patients with PVL were enrolled at 21 sites from 9 countries. Indications for PVL closure were heart failure and/or hemolytic anemia. Endpoint measures were changes in PV regurgitation grade, NYHA class and requirement for hemolysis-related transfusion. One-hundred thirty-six patients with mitral (67.6%) or aortic (32.4%) leaks were included (mean age 66.7 years, 58% men). Thirty-one percent had multiple PVLs. The proportion of patients with NYHA III/IV decreased from 77.3% at baseline to 16.9% at latest follow-up. The proportion of patients with need for hemolysis-related blood transfusion decreased from 36.8% to 5.9% and 8.3% to 0% for ML patients and AL patients, respectively. All cause mortality was 7.4%. Complications included interference with valve leaflets (0.7%), transient device embolization (percutaneously solved) (0.7%), late device embolization (0.7%), recurrent hemolytic anemia (2.2%), new onset hemolytic anemia (0.7%), valve surgery (2.2%), need for repeat closure (0.7%), complications at femoral puncture site (0.7%) and arrythmias requiring treatment (4.4%).
Conclusions: PVL closure with the Occlutech PLD demonstrated high success rate associated with significant clinical improvement and a relatively low rate of serious complications.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com